格隆汇1月19日丨天域生物(603717.SH)公布，公司预计2025年度实现归属于母公司所有者的净利润 为-12,500.00万元到-8,500.00万元；预计2025年度实现归属于母公司所有者的扣除非经常性损益后的净 利润为-16,500.00万元到-12,000.00万元。 ...

天域生物科技股份有限公司 2025 年年度业绩预告 证券代码：603717 证券简称：天域生物 公告编号：2026-010 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次业绩预告仅为初步核算数据，具体准确的财务数据以公司正式披露的 经审计后的 2025 年年度报告为准，敬请广大投资者注意投资风险。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经公司财务部门初步测算，预计 2025 年度实现归属于母公司所有者的净 利润为-12,500.00 万元到-8,500.00 万元。 2、公司预计 2025 年度实现归属于母公司所有者的扣除非经常性损益后的净 利润为-16,500.00 万元到-12,000.00 万元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期经营业绩和财务状况 1 业绩预告的适用情形：净利润为负值。 天域生物科技股份有限公司（以下简称"公司"）预计 2025 年度实现归 属于母公司所有者的净利润为 ...

Core Viewpoint - A-share listed companies are actively engaging in shareholder return activities, utilizing methods beyond cash dividends, such as offering products, services, discount coupons, or exclusive rights, with mixed market performance but overall outpacing the CSI 300 index [1] Group 1: Shareholder Return Activities - Approximately 130 companies have shown varied market performance, with some adopting creative ways to reward shareholders [1] - Companies are not only providing gifts but are also formulating future dividend plans, with 10 companies announcing shareholder return strategies for the next three years [1] Group 2: Dividend Plans and Performance - The top performers in terms of stock price increase since 2025 include Haoen Qidian (301488) with a rise of 205.66%, Shuiyang Co. (300740) at 87.59%, and Huasheng Co. (600156) at 69.18% [3] - Specific dividend plans include: - Haoen Qidian: Minimum 10% of distributable profit annually from 2025 to 2027 [3] - Shuiyang Co.: Cash dividends not less than 10% of distributable profit annually from 2025 to 2027 [3] - Huasheng Co.: Cumulative cash distribution of at least 30% of the average distributable profit over the last three years from 2026 to 2028 [3] - Other companies like Gais Food (36.36%) and Bona Film (34.26%) also have significant dividend commitments [3]

（记者 张明双） 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ 每经AI快讯，天域生物1月16日晚间发布公告称，公司股东史东伟先生持有公司股份约3234万股，占公 司总股本的11.15%，本次质押展期后，史东伟先生累计质押股份2900万股，占其持股数量的89.68%， 占公司总股本的9.99%。 ...

证券代码：603717 证券简称：天域生物 公告编号：2026-009 天域生物科技股份有限公司 关于持股 5%以上股东部分股份质押展期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股东史东伟先生持有公司股份 32,338,800 股，占公司总股本的 11.15%， 本次质押展期后，史东伟先生累计质押股份 29,000,000 股，占其持股数量 的 89.68%，占公司总股本的 9.99%。 相关股份不具有潜在业绩补偿义务的情况。 3、股东累计质押股份情况 | | | 1 | 持股数量（股） | | 32,338,800 | | --- | --- | --- | | 持股比例 | | 11.15% | | 本次质押展期前累计质押数量（股） | | 29,000,000 | | 本次质押展期后累计质押数量（股） | | 29,000,000 | | 占其所持股份比例 | | 89.68% | | 占公司总股本比例 | | 9.99% | | 已质押股份情况 | 已质押股份中限售股份数量（股） | ...

天域生物公告称，2026年1月16日收到持股5%以上股东史东伟书面函告，其将持有的1000万股公司股份 进行质押展期，占其所持股份比例30.92%，占公司总股本比例3.45%，原质押到期日为2026年1月15 日，展期后至2026年7月14日，质权人为上海张江科技小额贷款股份有限公司，资金用于补充流动资 金。史东伟持有公司股份3233.88万股，占总股本11.15%，本次质押展期后累计质押2900万股，占其持 股数量89.68%，占公司总股本9.99%。此外，其318.1856万股股份因合同纠纷被司法冻结。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）现将2025年12月养殖业务主要经营数据公告如下： 一、2025年12月养殖行业主要经营数据 2025年12月，公司销售生猪3.92万头，销售收入4,468.62万元，环比变动分别为122.41%、83.72%，同比 变动分别为39.48%、-24.74%。 2025年1-12月，公司累计销售生猪37.88万头，同比上升22.92%；累计销售收入51,920.70万元，同比下 降10.38%。 月度主要经营数据汇总如下： ■ 注：因四舍五入，以上数据可能存在尾差。 二、特别提示 1、上述经营数据均未经审计，与定期报告披露的数据之间可能存在差异，因此仅作为阶段性数据供投 资者参考。 2、基于生猪市场价格大幅波动以及公司投苗节奏变化等因素影响，未来公司生猪销售数量和销售收入 存在月度波动风险，敬请广大投资者注意投资风险。 天域生物科技股份有限公司董事会 2026年01月10日 2025年12月末，公司生猪存栏20.42万头，同比上升13.6 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

2025年1-12月，公司累计销售生猪37.88万头，同比上升22.92%；累计销售收入5.19亿元，同比下降 10.38%。 2025年12月末，公司生猪存栏20.42万头，同比上升13.65%，环比上升8.65%。 格隆汇1月9日丨天域生物(603717.SH)公布，公司现将2025年12月养殖业务主要经营数据公告如下： 2025年12月，公司销售生猪3.92万头，销售收入4468.62万元，环比变动分别为 122.41%、83.72%，同比 变动分别为39.48%、-24.74%。 ...

智通财经APP讯，天域生物(603717.SH)发布公告，2025年12月，公司销售生猪3.92万头，销售收入 4468.62万元，环比变动分别为122.41%、83.72%，同比变动分别为39.48%、-24.74%。2025年1-12月， 公司累计销售生猪37.88万头，同比上升22.92%;累计销售收入5.19亿元，同比下降10.38%。2025年12月 末，公司生猪存栏20.42万头，同比上升13.65%，环比上升8.65%。 ...